97207-47-1
基本信息
甲异靛
甲异靛, >96%
1-甲基-[3,3'-联吲哚基] -2,2'-二酮
N-甲基-(3,3'-双-二氢吲哚)-2,2'-二酮
Natura-α
Dian III
MEISOINDIGO
Meisoindigo, >96%
Methylisoindigotin
Meisoindigo, >=98%
Meisoindigo(Natura-
N-methylisoindigotin
Meisoindigo USP/EP/BP
物理化学性质
| 熔点 | 236-237°C |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | insoluble in H2O; insoluble in EtOH; ≥25.85 mg/mL in DMSO with ultrasonic |
| 形态 | 粉末晶体 |
| 颜色 | 橙色到棕色到深红色 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| 海关编码 | 2933.79.1500 |
常见问题列表
Meisoindigo (Dian III; 5-20 μM; for 24 hours) inhibits growth of the AML cell lines.
Meisoindigo (10 μM; for 24 hours) induces apoptosis of acute myeloid leukemia.
Meisoindigo (5-10 μM; for 24 hours) causes cell-cycle arrest.
Meisoindigo (5-10 μM; for 24 hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells.
Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells.
Cell Viability Assay
| Cell Line: | HL-60, NB4, U937 leukemic cell lines |
| Concentration: | 5, 10, 15, 20 μM |
| Incubation Time: | For 24 hours |
| Result: | Inhibited growth of the AML cell lines in a dose- and time-dependent manner. |
Apoptosis Analysis
| Cell Line: | HL-60 cells |
| Concentration: | 10 μM |
| Incubation Time: | For 24 hours |
| Result: | Induced apoptosis of acute myeloid leukemia. |
Cell Cycle Analysis
| Cell Line: | HL-60 cells |
| Concentration: | 5, 10 μM |
| Incubation Time: | For 24 hours |
| Result: | Caused cell-cycle arrest, with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase, in a dose-dependent manner. |
Western Blot Analysis
| Cell Line: | HL-60 cells |
| Concentration: | 5, 10 μM |
| Incubation Time: | For 24 hours |
| Result: | Increased the cleaved caspase-3 and pro-apoptotic Bak, and decreased Bcl-2 and Bcl-xL levels in HL-60 cells. |
Meisoindigo (Dian III; 50-150 mg/kg; IP; daily; for 14 days) has anti-leukemic activity in vivo.
Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain.
| Animal Model: | NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cells |
| Dosage: | 50, 100, 150 mg/kg |
| Administration: | IP; daily; for 14 days |
| Result: | Had anti-leukemic activity in vivo. |